Progress of researches on albendazole for treatment of alveolar echinococcosis
10.16250/j.32.1374.2022075
- VernacularTitle:阿苯达唑治疗多房棘球蚴病研究进展
- Author:
Ziyan CUI
1
,
2
,
3
;
Gengbo YE
1
,
2
,
3
;
Wenhao YU
3
,
4
;
Zhixin WANG
3
,
4
;
Fanyu KONG
3
,
4
;
Li REN
3
,
4
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, Qinghai University Affiliated Hospital, Xining, Qinghai 810012, China
2. Qinghai University Medical School, Xining, Qinghai 810012, China
3. Qinghai Provincial Key Laboratory of Echinococcosis Research, Xining, Qinghai 810099, China
4. Qinghai University Medical School, Xining, Qinghai 810012, China
- Publication Type:Journal Article
- Keywords:
Alveolar echinococcosis;
Albendazole;
Combination therapy
- From:
Chinese Journal of Schistosomiasis Control
2023;35(1):104-110
- CountryChina
- Language:Chinese
-
Abstract:
Alveolar echinococcosis, caused by Echinococcus multilocularis infection, is a highly deadly zoonotic parasitic disease. As a benzimidazole compound, albendazole has a strong and broad-spectrum anti-parasitic action. For alveolar echinococcosis patients that are unwilling to receive surgical treatment, lose the timing for surgery, or are intolerant to surgery due to poor physical status, administration of albendazole may delay disease progression. Recently, a large number of advances have been achieved in experimental studies on alveolar echinococcosis. In order to increase the understanding of the therapeutic efficacy of albendazole for alveolar echinococcosis, this review summarizes the advances in albendazole treatment for alveolar echinococcosis, so as to provide insights into the clinical treatment of alveolar echinococcosis with albendazole.
